#None #Abbott #Colorectal Cancer #Cologuard Plus

Abbott's Cologuard Plus® Receives CE Mark: A New Era for Colorectal Cancer Screening in Europe

Abbott has recently announced that its Cologuard Plus® test has achieved a significant regulatory milestone by receiving the CE Mark under the European Union’s In Vitro Diagnostic Medical Devices Regulation (IVDR). This marks a pivotal step towards enhancing the availability of non-invasive colorectal cancer screening in various European countries.

What is Cologuard Plus®?

Cologuard Plus® is a stool-based DNA screening test that is uniquely designed to identify both colorectal cancer and advanced precancerous lesions. Unlike traditional methods, it requires no bowel preparation, dietary changes, or sedation, making it an accessible option for many individuals. This ease of use is particularly crucial as it aims to facilitate higher participation rates in cancer screenings.

A Major Public Health Initiative

Colorectal cancer is a significant health crisis within Europe, with approximately 538,000 new cases diagnosed in 2022 alone. Among these, over 356,000 cases were reported within the European Union, accounting for about 13% of all new cancer cases. Despite the severity of this issue, screening participation varies widely across the continent. Reports suggest that only 42% of eligible individuals participated in screening efforts over the last two years, highlighting a pressing need for more effective outreach and screening options.

Significance of the CE Mark

With the CE Mark in hand, Abbott hopes to quickly roll out Cologuard Plus® in select European markets. The timing and availability of this service will differ by country based on local healthcare systems and reimbursement structures. As stated by Jake Orville, Senior Vice President of Abbott’s cancer diagnostics division, “Screening is one of the most powerful tools we have in the fight against colorectal cancer, but it only works when people complete it.” He emphasizes that Cologuard Plus enhances an already successful model that transformed cancer screening in the United States by allowing individuals to complete the screening in the comfort of their own homes.

Clinical Success in the BLUE-C Study

The effectiveness of Cologuard Plus was evaluated in the BLUE-C study, one of the largest prospective studies for colorectal cancer screening, involving over 20,000 participants. In this study, the test exhibited remarkable performance: 95% sensitivity for detecting colorectal cancer at a specificity of 94%. Furthermore, it demonstrated 43% sensitivity for advanced precancerous lesions and reduced false-positive rates by up to 40% compared to the original Cologuard test. Such impressive results provide strong validation for its use as a frontline screening tool.

Encouraging Broader Screening Participation

Dr. Cesare Hassan, a leading gastroenterologist from Humanitas University in Milan, Italy, points out that colorectal cancer remains a substantial public health challenge in Europe. He advocates for a collective effort to increase screening participation, noting that options like Cologuard Plus — which are accurate, non-invasive, and easy to use — could help identify cancers at more treatable stages.

By expanding access to innovative screening alternatives, Abbott aims to address the unmet needs for colorectal cancer screenings and ultimately improve patient outcomes across Europe.

Conclusion

Cologuard Plus® signifies a groundbreaking advancement in colorectal cancer prevention, aiming not only to streamline the screening process but also to make it more accessible for individuals across Europe. With Abbott’s proven expertise in healthcare technology, this new product has the potential to make a significant impact on public health by increasing screening rates and facilitating early detection of colorectal neoplasia. For more information about Cologuard Plus®, visit Abbott’s official website.